Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by JianXin Duan
OBI-3424, a Novel AKR1C3-activated Prodrug, Exhibits Potent Efficacy Against Preclinical Models of T-All
Clinical Cancer Research
Cancer Research
Oncology
Related publications
A Novel PI3K Inhibitor PIK-C98 Displays Potent Preclinical Activity Against Multiple Myeloma
Oncotarget
Oncology
Bisphosphonamidate Clodronate Prodrug Exhibits Potent Anticancer Activity in Non-Small-Cell Lung Cancer Cells
Journal of Medicinal Chemistry
Drug Discovery
Molecular Medicine
Dual Targeting of Aurora Kinases With AMG 900 Exhibits Potent Preclinical Activity Against Acute Myeloid Leukemia With Distinct Post-Mitotic Outcomes
Molecular Cancer Therapeutics
Cancer Research
Oncology
Sanguinarine Exhibits Potent Efficacy Against Cervical Cancer Cells Through Inhibiting the STAT3 Pathway in Vitro and in Vivo
Cancer Management and Research
Oncology
Preclinical Toxicity, Toxicokinetics, and Antitumoral Efficacy Studies of DTS-201, a Tumor-Selective Peptidic Prodrug of Doxorubicin
Clinical Cancer Research
Cancer Research
Oncology
Preclinical Testing of a Novel Personalized Cancer Vaccine for All Solid Tumors and All Patients
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
A Novel Vibriophage Exhibits Inhibitory Activity Against Host Protein Synthesis Machinery
Scientific Reports
Multidisciplinary
Nanoparticulate Vacuolar ATPase Blocker Exhibits Potent Host-Targeted Antiviral Activity Against Feline Coronavirus
Scientific Reports
Multidisciplinary
TAS0728, a Covalent-Binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models
Molecular Cancer Therapeutics
Cancer Research
Oncology
